Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial

Authors:

Abstract
No abstract available
Funding Information
  • AstraZeneca

This publication has 25 references indexed in Scilit: